Tag Archives: Elemer Piros

Tocagen Inc (TOCA) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros initiated coverage with a Buy rating on Tocagen Inc (TOCA – Research Report) today and set a price target of $28. The company’s shares opened today at $8.56. Piros commented: “$28 PT EPS 1Q 2Q

Cantor Fitzgerald Thinks Aldeyra Therapeutics’ Stock is Going to Recover

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Aldeyra Therapeutics (ALDX – Research Report) today and set a price target of $35. The company’s shares closed yesterday at $7.14, close to its 52-week low of $6.75. Piros said:

Cantor Fitzgerald Sticks to Its Buy Rating for Proteostasis Therapeutics Inc (PTI)

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Proteostasis Therapeutics Inc (PTI – Research Report) today and set a price target of $14. The company’s shares closed on Friday at $4.07. Piros commented: “: We reiterate our OW

Cantor Fitzgerald Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)

In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report), with a price target of $24. The company’s shares opened today at $6.42. Piros commented: “: We are reiterating

Cantor Fitzgerald Believes GW Pharma (NASDAQ: GWPH) Still Has Room to Grow

In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on GW Pharma (GWPH – Research Report), with a price target of $196. The company’s shares closed on Friday at $169.32, close to its 52-week high

PolarityTE Inc (PTE) Received its Third Buy in a Row

After Oppenheimer and Piper Jaffray gave PolarityTE Inc (NASDAQ: PTE) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Elemer Piros reiterated a Buy rating on PolarityTE Inc today and set a price